These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38517439)

  • 1. Clinical, Epidemiologic, and Pathologic Significance of ERBB2-Low Expression in Breast Cancer.
    Khoury T; Mendicino L; Payne Ondracek R; Yao S; Davis W; Omilian AR; Kwan ML; Roh JM; D'Addario L; Valice E; Fernandez D; Ergas IJ; Chua AV; Ambrosone CB; Kushi LH
    JAMA Netw Open; 2024 Mar; 7(3):e243345. PubMed ID: 38517439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
    Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age, Body Mass Index, Tumor Subtype, and Racial and Ethnic Disparities in Breast Cancer Survival.
    Lipsyc-Sharf M; Ballman KV; Campbell JD; Muss HB; Perez EA; Shulman LN; Carey LA; Partridge AH; Warner ET
    JAMA Netw Open; 2023 Oct; 6(10):e2339584. PubMed ID: 37878313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database.
    Peiffer DS; Zhao F; Chen N; Hahn OM; Nanda R; Olopade OI; Huo D; Howard FM
    JAMA Oncol; 2023 Apr; 9(4):500-510. PubMed ID: 36821125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B; Yau C; Campbell MJ; Yoshimatsu TF; Chien AJ; Wallace AM; Forero-Torres A; Pusztai L; Ellis ED; Albain KS; Blaes AH; Haley BB; Boughey JC; Elias AD; Clark AS; Isaacs CJ; Nanda R; Han HS; Yung RL; Tripathy D; Edmiston KK; Viscusi RK; Northfelt DW; Khan QJ; Asare SM; Wilson A; Hirst GL; Lu R; Symmans WF; Yee D; DeMichele AM; van 't Veer LJ; Esserman LJ; Olopade OI
    JAMA Netw Open; 2023 Dec; 6(12):e2349646. PubMed ID: 38153734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis.
    Tan RSYC; Ong WS; Lee KH; Lim AH; Park S; Park YH; Lin CH; Lu YS; Ono M; Ueno T; Naito Y; Onishi T; Lim GH; Tan SM; Lee HB; Ryu HS; Han W; Tan VKM; Wong FY; Im SA; Tan PH; Chan JY; Yap YS
    BMC Med; 2022 Mar; 20(1):105. PubMed ID: 35296300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
    Tarantino P; Jin Q; Tayob N; Jeselsohn RM; Schnitt SJ; Vincuilla J; Parker T; Tyekucheva S; Li T; Lin NU; Hughes ME; Weiss AC; King TA; Mittendorf EA; Curigliano G; Tolaney SM
    JAMA Oncol; 2022 Aug; 8(8):1177-1183. PubMed ID: 35737367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US.
    Shubeck S; Zhao F; Howard FM; Olopade OI; Huo D
    JAMA Netw Open; 2023 Mar; 6(3):e235834. PubMed ID: 36995711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
    de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
    JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional Recurrence Patterns in Patients With Different Molecular Subtypes of Breast Cancer.
    Cheun JH; Kim HK; Moon HG; Han W; Lee HB
    JAMA Surg; 2023 Aug; 158(8):841-852. PubMed ID: 37342035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features and Prognoses of Patients With Breast Cancer Who Underwent Surgery.
    Liu G; Kong X; Dai Q; Cheng H; Wang J; Gao J; Wang Y
    JAMA Netw Open; 2023 Aug; 6(8):e2331078. PubMed ID: 37624596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer.
    Zagami P; Fernandez-Martinez A; Rashid NU; Hoadley KA; Spears PA; Curigliano G; Perou CM; Carey LA
    JAMA Netw Open; 2023 Dec; 6(12):e2348814. PubMed ID: 38117494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
    Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
    JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women.
    Hoskins KF; Danciu OC; Ko NY; Calip GS
    JAMA Oncol; 2021 Mar; 7(3):370-378. PubMed ID: 33475714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials.
    Fernandez-Martinez A; Pascual T; Singh B; Nuciforo P; Rashid NU; Ballman KV; Campbell JD; Hoadley KA; Spears PA; Pare L; Brasó-Maristany F; Chic N; Krop I; Partridge A; Cortés J; Llombart-Cussac A; Prat A; Perou CM; Carey LA
    JAMA Oncol; 2023 Apr; 9(4):490-499. PubMed ID: 36602784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
    Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
    JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis.
    Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA
    Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.